Drug Hunter

JULY 21, 2023

vorasidenib – An oral first-in-class dual IDH1/IDH2 inhibitor with efficacy in Phase III trials for IDH-mutant grade 2 gliomas, discovered through structure-based drug design (SBDD) of a prior mIDH inhibitor, developed by Agios and Servier.

Structure Based Drug Design (SBDD) 227

Structure Based Drug Design (SBDD) Targeted Protein Degradation Clinical Trials Trials 227

Drug Discovery World

AUGUST 4, 2022

Biopharmaceutical group Sosei will work together with AbbVie on a drug discovery project to discover, develop and commercialise small molecules that target neurological diseases. . The new agreement will see Sosei Heptares conduct and fund R&D activities through the completion of Investigational New Drug (IND)-enabling studies.

Structure Based Drug Design (SBDD) 130

Structure Based Drug Design (SBDD) Small Molecule Drugs Licensing 130

The Pharma Data

SEPTEMBER 29, 2020

The collaboration has leveraged Sosei’s StaR technology and Structure-based Drug Design (SBDD) capabilities to design oral small molecules that modulate different G protein-coupled receptor (GPCR) targets across multiple disease areas.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Small Molecule Clinical Trials Pharma Companies 52

The Pharma Data

NOVEMBER 19, 2020

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. . TOKYO and CAMBRIDGE, England , Nov.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. Captor’s Optigradeä platform is focused on improving the selectivity and performance of first-generation degrader drugs.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

Drug Discovery World

JUNE 12, 2023

Iktos’ Makya generative AI technology aims to bring new insights and directions into the molecular discovery process by automatically designing virtual novel molecules that have desired activities for treating a given disease.

Structure Based Drug Design (SBDD) 130

Structure Based Drug Design (SBDD) Drugs Production Disease 130

The Pharma Data

JANUARY 31, 2021

. Joint drug discovery program to focus on a single ion channel that is a well-validated target for neurological diseases. They are well established drug targets, particularly in neurological and cardiovascular diseases, but many remain undrugged or poorly drugged, and may be tractable to structure-based approaches.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Targeted Protein Degradation Drugs International 52